Rituximab in primary conjunctiva lymphoma.
Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye.
Zinzani
Pier Luigi
PL
Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy. plzinzo@med.unibo.it
Alinari
Lapo
L
Stefoni
Vittorio
V
Loffredo
Antonio
A
Pichierri
Patrizia
P
Polito
Ennio
E
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab